Loading stock data…
Nurix Therapeutics, Inc. (NRIX)
$23.85+0.95 (+4.15%)
After Hours$24.10+0.25 (+1.04%)· Last close Jun 29
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nurix Therapeutics, Inc. in the Healthcare sector is trading at $23.85 with a market capitalization of $1.6B. Wall Street consensus targets $31.44 (16 analysts), implying a +31.8% move over the next 12 months. The stock is currently near its 52-week high of $24.03, remaining 54.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +31.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.25M↓ | $13.58M↑ | $7.89M↓ | $44.06M↑ | $18.45M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$92.50M↓ | -$83.09M↑ | -$91.39M↓ | -$48.32M↑ | -$62.86M |
| Net Income | -$87.17M↓ | -$78.22M↑ | -$86.42M↓ | -$43.46M↑ | -$56.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.40%
Volume
Today's trading volume
2.42M
Recent News
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer
Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the 9 Stocks Winning by Double Digits. Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions following an earlier partnership with Roche for the co-development of a blood cancer treatment. In intra-day trading, the stock […]
Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target
Nurix Therapeutics (NRIX) has drawn investor attention after recent trading, with the stock closing at $17.04. The move comes as the clinical stage biotech continues to develop its pipeline of targeted therapies. See our latest analysis for Nurix Therapeutics. The recent 8.95% 7 day share price return and 10.08% 90 day share price return sit alongside a year to date share price decline of 5.65%. The 1 year total shareholder return of 43.07% points to momentum that has improved over a longer...
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 9, Truist analyst Gregory Renza raised Nurix Therapeutics, Inc. (NASDAQ:NRIX)’ price target to $32 from $30. The firm maintained a “Buy” rating on the shares. The analyst called the company’s partnership with Roche “strategically sensible.” It […]
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Canopy Growth (CGC) delivered earnings and revenue surprises of -199.82% and -2.47%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?